• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Drug regulation
Tag:

Drug regulation

Health

European Patient Advocacy Groups: A Collaborative Network for Research & Healthcare

by Chief Editor January 6, 2026
written by Chief Editor

The Growing Power of Patient Advocacy Groups in Shaping Healthcare’s Future

The landscape of healthcare is undergoing a significant shift, and at the forefront of this change is the increasing influence of patient advocacy groups. Traditionally, medical research and policy were largely driven by clinicians and pharmaceutical companies. Now, a powerful chorus of patient voices, represented by organizations like those listed below, is demanding a seat at the table – and they’re getting it.

This isn’t simply about raising awareness. These groups are actively involved in research prioritization, clinical trial design, policy lobbying, and even direct funding of innovative projects. The affiliations listed – representing conditions from leukemia and kidney cancer to cystic fibrosis and reproductive health – demonstrate the breadth of this movement.

Why This Shift is Happening Now

Several factors are converging to empower patient advocacy. The internet and social media have enabled patients to connect, share experiences, and organize more effectively. Increased transparency in research and a growing demand for patient-centered care are also playing a role. Furthermore, funding agencies, like the European Commission, are increasingly requiring patient involvement in funded projects.

Did you know? A 2023 study by the Patient Empowerment Network found that 78% of patients believe their input is crucial to improving healthcare outcomes.

The Impact on Medical Research

Historically, research agendas were often determined by what was scientifically feasible or commercially viable. Now, patient groups are helping to identify unmet needs and prioritize research that directly addresses those needs. They’re also contributing to clinical trial design, ensuring trials are relevant and accessible to the people they’re intended to help.

For example, the Leukemia & Lymphoma Society (LLS) has invested heavily in blood cancer research, funding innovative therapies and accelerating the development of new treatments. Similarly, the Cystic Fibrosis Foundation’s aggressive fundraising and strategic investments have been instrumental in the development of life-changing therapies for cystic fibrosis.

Policy and Advocacy: A Growing Force

Patient advocacy groups are becoming increasingly sophisticated in their lobbying efforts. They’re working to influence policy decisions at the national and European levels, advocating for increased funding for research, improved access to care, and policies that support patients’ rights.

The European Renal Association (ERA) actively lobbies for improved kidney health policies across Europe, while the European Cancer Organisation (ECO) champions comprehensive cancer control strategies. This direct engagement with policymakers is ensuring that the patient perspective is considered when crucial decisions are made.

The Rise of Patient-Reported Outcomes (PROs)

One of the most significant contributions of patient advocacy is the emphasis on Patient-Reported Outcomes (PROs). PROs capture the patient’s perspective on their health, including symptoms, functional status, and quality of life. This information is invaluable for understanding the true impact of a disease and evaluating the effectiveness of treatments.

Pro Tip: When participating in clinical trials, actively share your experiences and perspectives with the research team. Your input can help improve the trial and benefit future patients.

Challenges and Future Trends

Despite the progress, challenges remain. Ensuring diverse representation within patient advocacy groups is crucial, as is addressing potential conflicts of interest. Maintaining scientific rigor and avoiding the spread of misinformation are also important considerations.

Looking ahead, we can expect to see:

  • Increased Collaboration: More partnerships between patient groups, researchers, and industry.
  • Data-Driven Advocacy: Greater use of data analytics to demonstrate the impact of advocacy efforts.
  • Personalized Medicine Focus: Patient groups will play a key role in advocating for personalized medicine approaches tailored to individual needs.
  • Digital Health Integration: Leveraging digital health technologies to connect patients, collect data, and deliver support.

FAQ

Q: What is the role of a patient advocacy group?
A: They represent the interests of patients, advocate for improved care and research, and provide support and education.

Q: How can I get involved with a patient advocacy group?
A: Search online for organizations related to your condition or visit websites like the National Organization for Rare Disorders (NORD).

Q: Are patient advocacy groups funded by pharmaceutical companies?
A: Some receive funding from industry, but reputable organizations are transparent about their funding sources and have policies in place to manage potential conflicts of interest.

Q: How do patient advocacy groups influence research?
A: They help prioritize research areas, contribute to clinical trial design, and fund research projects.

Q: What are Patient-Reported Outcomes (PROs)?
A: These are measures of a patient’s health status that come directly from the patient, capturing their symptoms, functional status, and quality of life.

Want to learn more about patient empowerment and healthcare innovation? Explore our other articles or subscribe to our newsletter for the latest updates.

January 6, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Pharma MNCs Won’t Sell Drugs To Doctors Without Valid APC

by Chief Editor January 6, 2026
written by Chief Editor

Malaysia’s Healthcare Supply Chain: A Looming Crisis and the Future of Regulation

A recent standoff between pharmaceutical companies and medical practitioners in Malaysia highlights a critical vulnerability in the nation’s healthcare system: the reliance on Annual Practising Certificates (APCs) and the potential for disruption when the issuing process falters. Multinational drug makers, represented by the Pharmaceutical Association of Malaysia (PhAMA), have begun refusing sales to doctors without valid 2026 APCs, even as the Malaysian Medical Council (MMC) attempts to mitigate a significant backlog of applications.

The APC Bottleneck: Why It Matters

The core issue isn’t simply bureaucratic delay. It’s about legal compliance and patient safety. The Poisons Act 1952 dictates who can legally procure and administer medications. PhAMA, representing 41 multinational corporations, is prioritizing adherence to these regulations. This primarily impacts private General Practitioner (GP) clinics, where doctors typically manage their own drug supplies, unlike larger hospitals and public facilities which rely on pharmacist-led procurement.

The MMC’s attempt to allow doctors with pending applications to continue practicing, while well-intentioned, is facing legal challenges. Experts like lawyer Manmohan Singh Dhillon argue the MMC lacks the legal authority to waive the APC requirement, citing the Medical Act 1971. This creates a precarious situation: doctors potentially practicing and prescribing without legal standing, and patients facing potential disruptions in access to necessary medications.

Did you know? Malaysia saw a surge in illegal medicines sold online in 2025, according to the then Deputy Health Minister Lukanisman Awang Sauni. This underscores the importance of a robust and legally sound pharmaceutical supply chain.

Beyond the Immediate Crisis: Future Trends in Healthcare Regulation

This situation isn’t an isolated incident; it’s a symptom of broader trends reshaping healthcare regulation in Malaysia and globally. Several key shifts are likely to accelerate in the coming years:

1. Digitalization of Credentials and Licensing

The current APC backlog points to the urgent need for a fully digitalized system for managing medical credentials. A centralized, real-time database accessible to both practitioners and pharmaceutical suppliers would eliminate ambiguity and streamline verification. Countries like Singapore and Estonia are already leading the way with digital identity and licensing solutions. Malaysia’s MySejahtera app, initially designed for COVID-19 contact tracing, could potentially be expanded to incorporate secure digital APC verification.

2. Enhanced Supply Chain Traceability with Blockchain

The rise of counterfeit drugs and the challenges of tracking medication from manufacturer to patient necessitate greater supply chain transparency. Blockchain technology offers a promising solution. By creating an immutable record of each transaction, blockchain can verify the authenticity of drugs and prevent the entry of substandard or falsified products. Pilot programs using blockchain for pharmaceutical supply chain management are already underway in several countries, including the United States and India.

3. The Rise of Telemedicine and Remote Prescribing – A Regulatory Catch-Up

Telemedicine is rapidly gaining acceptance in Malaysia, particularly in underserved areas. However, current regulations surrounding remote prescribing are unclear and often tied to the physical APC. As telemedicine expands, the regulatory framework must adapt to accommodate virtual consultations and electronic prescriptions, ensuring patient safety and legal compliance. This will likely involve establishing clear guidelines for verifying patient identity remotely and ensuring secure data transmission.

4. Increased Focus on Pharmacovigilance and Data Analytics

With a growing emphasis on personalized medicine and the increasing complexity of drug therapies, robust pharmacovigilance systems are crucial. Leveraging data analytics and artificial intelligence (AI) to identify adverse drug reactions and monitor drug utilization patterns will become increasingly important. This requires collaboration between healthcare providers, pharmaceutical companies, and regulatory agencies to share data and improve patient safety.

Pro Tip: Healthcare professionals should proactively ensure their APC applications are submitted well in advance of the expiry date to avoid disruptions in practice and potential legal issues.

The Legal Gray Area: Prescribing Without a Valid APC

The question of whether doctors can legally prescribe medications without a valid APC remains contentious. While the MMC’s statement offered temporary relief, legal experts warn that it doesn’t override the provisions of the Medical Act 1971. Practicing medicine and charging fees without a valid APC are explicitly prohibited. This creates a significant risk for practitioners, potentially exposing them to legal action and professional sanctions.

Azrul Mohd Khalib, CEO of the Galen Centre for Health and Social Policy, emphasizes that the MMC’s “waiver” doesn’t negate the legal requirements. This highlights the need for clear and unambiguous guidance from the Ministry of Health (MOH) to resolve the ambiguity and protect both doctors and patients.

FAQ: Navigating the APC Crisis

  • Q: Can doctors continue practicing if their APC application is pending?
    A: The MMC has allowed practice pending issuance, but this is legally questionable and doesn’t permit charging fees.
  • Q: What happens if a GP runs out of medication due to the APC issue?
    A: They must issue prescriptions for patients to fill at a pharmacy.
  • Q: Is the MMC’s decision legally sound?
    A: Legal experts argue it lacks legal authority under the Medical Act 1971.
  • Q: What is PhAMA’s role in this situation?
    A: PhAMA is enforcing compliance with the Poisons Act 1952 and prioritizing patient safety.

This situation serves as a wake-up call for Malaysia’s healthcare system. Addressing the APC backlog is just the first step. A comprehensive overhaul of healthcare regulation, embracing digitalization, blockchain technology, and a proactive approach to emerging trends like telemedicine, is essential to ensure a safe, efficient, and accessible healthcare system for all Malaysians.

Further Reading:

  • CodeBlue: MMC Issues Mea Culpa, Allows Doctors to Practise Pending APC
  • Free Malaysia Today: Still an Offence Despite MMC Directive on Certs, Say Lawyers

What are your thoughts on the future of healthcare regulation in Malaysia? Share your comments below!

January 6, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

BSVA: blockchain-enabled secured vertical aggregation algorithm for transactions management in drug traceability framework

by Chief Editor July 31, 2025
written by Chief Editor

Blockchain’s Transformative Touch: Shaping the Future of Pharmaceutical Supply Chains

The pharmaceutical industry is undergoing a seismic shift, and at the heart of this transformation lies blockchain technology. From drug traceability to secure data sharing, blockchain’s potential is vast. In this article, we’ll delve into the key trends and future possibilities for this groundbreaking technology within the pharmaceutical supply chain, drawing on real-world examples and expert insights.

Traceability: A Foundation for Trust

One of the most immediate benefits of blockchain in pharma is enhanced drug traceability. Imagine a world where counterfeit medications are virtually eliminated. That’s the promise of blockchain. By creating an immutable record of a drug’s journey from manufacturer to patient, blockchain empowers transparency, ensuring the integrity of pharmaceutical products. Using frameworks like Hyperledger (as referenced in the source article), companies can track a product’s movement, verifying its authenticity and preventing the entry of fake drugs into the market.

Did you know? Counterfeit drugs account for a significant percentage of the global pharmaceutical market, posing serious health risks. Blockchain provides a robust solution to combat this issue.

Enhanced Supply Chain Management

The source article highlights the use of Hyperledger to improve supply chain management. Blockchain simplifies this process by streamlining transactions and automating processes. With real-time visibility into every step of the supply chain, stakeholders can quickly identify bottlenecks, reduce waste, and optimize efficiency. This ultimately leads to faster delivery times and lower costs for consumers.

Pro Tip: Implementing blockchain requires careful planning and collaboration. Start with a pilot program to test the technology before a full-scale rollout.

Securing Sensitive Data

Pharmaceuticals deal with highly sensitive patient data. Blockchain offers a secure way to manage and share this information. Using encrypted data and access control, only authorized parties can view specific data points, ensuring patient privacy while enabling data-driven insights. This is particularly crucial for clinical trials and research, where data integrity is paramount. The use of smart contracts for automating processes further streamlines the process. The aggregation and sharing of data, as described in the provided text, is crucial to enable this.

The text discusses several methodologies: consensus techniques, access controls, and the use of specialized channels for secure sharing. These concepts will become even more important in the future.

Smart Contracts and Automation

Smart contracts, self-executing agreements encoded on the blockchain, are revolutionizing the pharmaceutical industry. These contracts automate various processes, such as payments, regulatory compliance, and supply chain logistics. This reduces manual intervention, minimizes errors, and accelerates transactions. The text demonstrates this with examples in the drug traceability and vertical aggregation models.

Key Trends Shaping the Future

Several trends are driving the evolution of blockchain in pharma:

  • Increased Adoption: More pharmaceutical companies are investing in blockchain solutions. Expect rapid adoption in the coming years.
  • Interoperability: The ability of different blockchain platforms to communicate and share data will be essential.
  • Integration with AI: Combining blockchain with AI will unlock even greater potential, such as predicting supply chain disruptions.
  • Regulatory Compliance: Meeting regulatory requirements will be crucial. Organizations such as the FDA are already exploring the applications of blockchain for traceability.

Overcoming Challenges

Despite the promise, challenges remain. Implementing blockchain requires industry-wide collaboration and standardization. Scalability and data privacy are also important considerations. However, as technology evolves and best practices emerge, these challenges are being addressed.

FAQ: Your Questions Answered

Q: What is blockchain?
A: Blockchain is a decentralized, distributed, and immutable ledger that records transactions in a secure and transparent manner.

Q: How does blockchain improve drug traceability?
A: Blockchain creates a secure, transparent record of a drug’s journey, from origin to patient, preventing counterfeiting and ensuring authenticity.

Q: What are smart contracts?
A: Smart contracts are self-executing agreements that automate processes on a blockchain.

The Road Ahead

Blockchain is poised to reshape the pharmaceutical industry. Its impact on drug traceability, supply chain management, and data security is undeniable. As the technology matures and adoption grows, we can expect even more innovation. Those who embrace blockchain will be at the forefront of this transformation. This will reduce costs, improve patient outcomes, and increase the trust of customers. The framework illustrated within the source article provides an excellent outline for the future.

Ready to learn more? Explore our other articles on technology and supply chain management, and subscribe to our newsletter for the latest updates. What are your thoughts on the future of blockchain in the pharmaceutical industry? Share your comments below!

July 31, 2025 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • Modena vs Frosinone Live: Frosinone Leads 2-1 in Serie B

    April 18, 2026
  • FC Cincinnati Foundation Soccer Field Grants

    April 18, 2026
  • It doesn’t matter how much you sit — walking more could lower your risk of death and disease

    April 18, 2026
  • SpaceSlog, a spaceship builder colony sim. Released now on Steam

    April 18, 2026
  • Czech Justice Ministry: No info yet about Zaldy Co, but now ‘in contact’ with police

    April 18, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World